OrthoPediatrics Corp. (NASDAQ:KIDS) CFO Fred Hite Sells 6,443 Shares

OrthoPediatrics Corp. (NASDAQ:KIDS) CFO Fred Hite sold 6,443 shares of the company’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $160,172.98. Following the completion of the sale, the chief financial officer now directly owns 207,989 shares of the company’s stock, valued at $5,170,606.54. The trade was a 3.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

OrthoPediatrics Stock Performance

NASDAQ:KIDS opened at $25.42 on Wednesday. OrthoPediatrics Corp. has a 1 year low of $21.02 and a 1 year high of $35.99. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68. The business has a fifty day simple moving average of $24.79 and a two-hundred day simple moving average of $25.53. The company has a market capitalization of $617.38 million, a P/E ratio of -20.67 and a beta of 1.22.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The business had revenue of $52.67 million for the quarter, compared to analysts’ expectations of $51.16 million. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. During the same period in the previous year, the business posted ($0.23) EPS. On average, analysts expect that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of KIDS. Quarry LP purchased a new stake in shares of OrthoPediatrics during the third quarter worth $25,000. R Squared Ltd purchased a new stake in OrthoPediatrics during the 4th quarter worth about $48,000. KLP Kapitalforvaltning AS bought a new position in OrthoPediatrics in the 4th quarter worth about $79,000. BNP Paribas Financial Markets boosted its stake in OrthoPediatrics by 125.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company’s stock worth $94,000 after purchasing an additional 1,929 shares during the period. Finally, Quantbot Technologies LP increased its position in shares of OrthoPediatrics by 42.2% during the third quarter. Quantbot Technologies LP now owns 5,773 shares of the company’s stock valued at $157,000 after buying an additional 1,712 shares during the period. 69.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on KIDS. Stifel Nicolaus reduced their target price on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, March 5th. Needham & Company LLC restated a “buy” rating and issued a $42.00 price objective on shares of OrthoPediatrics in a research note on Wednesday, March 5th. Finally, Truist Financial cut their price target on shares of OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.